Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial

By sjmartinez • October 28, 2022

Choudhary MC, Chew KW, Deo R, Flynn JP, Regan J, Crain CR, Moser C, Hughes MD, Ritz J, Ribeiro RM, Ke R, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Fletcher CV, Daar ES, Wohl DA, Eron JJ, Currier JS, Parikh UM, Sieg SF, Perelson AS, Coombs RW, Smith DM, Li JZ; ACTIV-2/A5401 Study Team. Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial. Nat Microbiol. 2022 Nov;7(11):1906-1917. doi: 10.1038/s41564-022-01254-1. Epub 2022 Oct 26. PMID: 36289399.

Tags: Infectious Diseases, Publications

HIV Drug Resistance to Dolutegravir Among Adults Investigated for Anti-retroviral Treatment Failure in Malawi: A 2023 National Cross-sectional Survey

Kalata NL, Bello G, Pals S, Kabaghe AN, Mkungudza J, Bighignoli B, Panja L, Bilaal W, Kusakale G, Chitenje M, Luhanga M, Zeh C, Kampira[...]

Frailty, Pitavastatin, and Major Adverse Cardiovascular Events Among People With HIV

Erlandson KM, Orkaby AR, Umbleja T, Ribaudo HJ, Brown TT, Zanni MV, Diggs MR, Chu SM, Fitch KV, Fichtenbaum CJ, Malvestutto C, Aberg JA, Bloomfield[...]

Late BK Nephropathy 15 years post kidney transplant following chemotherapy: A case report

Hamiduzzaman A, Hou J, Higgins T, Gaynor P, Shankar A, Lum EL. Late BK Nephropathy 15 years post kidney transplant following chemotherapy: A case report.[...]